Skip to main content

Synergus

  • Home
  • About
    • Our Publications
    • Employment Opportunities
    • Intern/Thesis Opportunities
    • Find Us
    • Privacy Policy
    • Contact Us
    • IGES group
  • RWE impact
    • Data that makes the difference
    • Real World Data / Statistical analysis
    • Evidence For Decisions
  • Market Access
    • Countries
    • Diagnostics
    • Digital Health
    • Medical Device
      • Market access strategy
      • Hands-on market access support
      • Reimbursement dossier / HTA dossier
      • Reimbursement/DRG analysis
    • Pharma
  • HEOR
    • Health Economics
      • Cost Effectiveness and Budget Impact Modelling
      • Economic Outcomes in Clinical Studies
    • Value Demonstration
  • Events/Webinars
  • News
  • Blog

  • Home
  • About
    • Our Publications
    • Employment Opportunities
    • Intern/Thesis Opportunities
    • Find Us
    • Privacy Policy
    • Contact Us
  • RWE impact
    • Data that makes the difference
    • Real World Data / Statistical analysis
    • Evidence For Decisions
  • Market Access
    • Countries
    • Diagnostics
    • Digital Health
    • Medical Device
      • Market access strategy
      • Reimbursement/DRG analysis
      • Reimbursement dossier / HTA dossier
      • Hands-on market access support
    • Pharma
  • HEOR
    • Health Economics
      • Cost Effectiveness and Budget Impact Modelling
      • Economic Outcomes in Clinical Studies
    • Value Demonstration
  • Events/Webinars
  • News
  • Blog

Blog

Finnish Real World-World data sources – National registries
05 Oct 2022

Tags:
HQ_RWDFinlandReal World Data
read more
Swedish Real-World data sources – National registries
08 Sep 2022

Tags:
HQ_RWDSwedenReal World Data
read more
High quality RWE - Registry based randomized clinical trials
31 Aug 2022

Tags:
Real World EvidenceSwedenHQRWE_FractureR-RCT
read more
High-quality RWE – Transparency about data quality
10 Aug 2022

Tags:
Real World EvidenceSwedenHQRWE_Fracture
read more
Reimbursement may not be the primary barrier for digital health!?
04 Mar 2022

Tags:
Digital HealthGermanyDHS Germany
read more
The German NUB process, the most risky process for a start-up?
08 Feb 2022

Tags:
GermanyCoverage with Evidence DevelopmentInnovation Funding
read more
The best real-world data setting for diabetes research – How much data is required?
21 Jan 2022

The Swedish setting provides an extremely rich data set with very high quality for diabetes research.

Tags:
DiabetesReal World EvidenceReal World DataHQ_RWD
read more
Pharma blog
20 Dec 2020

More pharma blog's will come.

Tags:
Pharma
read more
Five digital solutions approved for temporary reimbursement in Germany – Up to 2000 €/year in reimbursement
09 Nov 2020

Tags:
Digital HealthGermanyDHS Germany
read more
Do we know what the problem is that we are trying to solve regarding the COVID-19 Pandemic?
27 Mar 2020

Tags:
COVID-19
read more
  • Show More

Contact us

Tags

Breast cancer
Corona virus
DHS France
EMA
EQ-5D
EU HTAR
EU HTAR IVD
EU HTAR Medtech
Germany
HQ_RWD
Imaging
Myeloma
Obesity
Patient Registries
Pharma
RWD Scientific Impact
RWD_DK
Transferability of Outcomes
Coverage with Evidence Development
DHS Germany
Italy
Melanoma
Multiple Sclerosis
Quality of Life
R-RCT
Registries
SF-36
DHS Belgium
Funding
HQRWE_Fracture
Netherlands
Rheumatoid Arthritis
Throat Cancer
Co-payment
Empowered Patients
Lung Cancer
Norway
Stroke
Digital Heath Strategies
France
Innovation Funding
Mental Health
Data Science in Oncology
Finland
Heart Failure
Out-patient procedures
Artificial Intelligence
Denmark
Diabetes
Dementia
Sweden
Alzheimer
The Netherlands
Oncology
United Kingdom
Country specific
China
COVID-19
Value Based Healthcare
HTA
RefugeeMD
Medical Device
Disease Specific
Health Economics
Legislation
Market Access
IVD
Digital Health
Real World Data
Real World Evidence
  • Home
  • About
  • RWE impact
  • Market Access
  • HEOR
  • Events/Webinars
  • News
  • Blog